- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05564221
A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Mild Allergic Diseases
A Randomized, Double-Blind, Placebo/Active Controlled, Multiple Ascending Dose, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of YH35324 in Atopic Healthy Subjects or Subjects With Mild Allergic Diseases
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: YouJin Sung
- Phone Number: +82 2-828-0622
- Email: yjsung@yuhan.co.kr
Study Contact Backup
- Name: Jungwook Lee
- Phone Number: 02-828-0504
- Email: ljw0914@yuhan.co.kr
Study Locations
-
-
-
Seoul, Korea, Republic of, 05505
- Recruiting
- Asan Medical Center
-
Seoul, Korea, Republic of, 06591
- Recruiting
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Korea, Republic of, 13620
- Recruiting
- Seoul National University Bundang Hospital
-
Suwon-si, Gyeonggi-do, Korea, Republic of, 16499
- Recruiting
- Ajou University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female adults aged ≥ 19 to ≤ 55 years
- Serum total IgE level ≥ 30 IU/mL or 30 to 700 IU/mL or >700IU/mL
- Healthy subjects without any pathological symptoms or findings from medical examination, or subjects with a history of mild allergic diseases (allergic rhinitis, atopic dermatitis, food allergy, urticaria, or allergic asthma)
Exclusion Criteria:
- History of malignancy
- Positive drug screen result
- Aspartate transaminase (AST) or alanine transaminase (ALT) level > 2 X the upper limit of normal
- Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula
- Allergy immunotherapy initiated or changed within 6 months prior to randomization
- History of participation in another clinical trial within 6 months prior to randomization
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: YH35324
There will be 4 dose groups of YH35324, escalating from low to high doses in a stepwise manner: 0.75 (Q2W), 3 (Q4W), 6 (Q4W), 6 (Q8W) mg/kg (Cohort 1 → Cohort 2, Cohort 2 → Cohorts 3 and 4). YH35324 and placebo will be administered in a double-blinded manner. |
Subcutaneous injection of YH35324
|
Placebo Comparator: Placebo
There will be 4 dose groups of YH35324, escalating from low to high doses in a stepwise manner: 0.75 (Q2W), 3 (Q4W), 6 (Q4W), 6 (Q8W) mg/kg (Cohort 1 → Cohort 2, Cohort 2 → Cohorts 3 and 4). YH35324 and placebo will be administered in a double-blinded manner. |
Subcutaneous injection of None of active ingredient
|
Active Comparator: Omalizumab
For Cohort 3, omalizumab 300 mg will be administered in an open-label manner.
|
Subcutaneous injection of Omalizumab
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence and severity of adverse events (AEs)
Time Frame: Occurrence and severity of adverse events will be observed for 141 days after administration
|
To evaluate the safety and tolerability following multiple administrations of YH35324
|
Occurrence and severity of adverse events will be observed for 141 days after administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Serum Concentration-Time Curve from Zero to the Time of the Last Quantitative Concentration (AUClast)
Time Frame: Serum concentrations of YH35324 will be observed for 141 days after administration
|
To evaluate the PK profile of YH35324
|
Serum concentrations of YH35324 will be observed for 141 days after administration
|
Area Under the Serum Concentration-Time Curve from Zero to Infinity (AUCinf)
Time Frame: Serum concentrations of YH35324 will be observed for 141 days after administration
|
To evaluate the PK profile of YH35324
|
Serum concentrations of YH35324 will be observed for 141 days after administration
|
Maximum Serum Concentration(Cmax)
Time Frame: Serum concentrations of YH35324 will be observed for 141 days after administration
|
To evaluate the PK profile of YH35324
|
Serum concentrations of YH35324 will be observed for 141 days after administration
|
Time to Maximum Serum Concentration (Tmax)
Time Frame: Serum concentrations of YH35324 will be observed for 141 days after administration
|
To evaluate the PK profile of YH35324
|
Serum concentrations of YH35324 will be observed for 141 days after administration
|
Terminal Elimination Rate Constant, Apparent Terminal Elimination Half-life (t1/2)
Time Frame: Serum concentrations of YH35324 will be observed for 141 days after administration
|
To evaluate the PK profile of YH35324
|
Serum concentrations of YH35324 will be observed for 141 days after administration
|
Apparent Serum Clearance (CL/F)
Time Frame: Serum concentrations of YH35324 will be observed for 141 days after administration
|
To evaluate the PK profile of YH35324
|
Serum concentrations of YH35324 will be observed for 141 days after administration
|
Apparent Volume of Distribution (Vz/F)
Time Frame: Serum concentrations of YH35324 will be observed for 141 days after administration
|
To evaluate the PK profile of YH35324
|
Serum concentrations of YH35324 will be observed for 141 days after administration
|
Area Under the Serum Concentration-Time Curve during dosing interval at steady-state (AUCtau)
Time Frame: Serum concentrations of YH35324 will be observed for 141 days after administration
|
To evaluate the PK profile of YH35324
|
Serum concentrations of YH35324 will be observed for 141 days after administration
|
Maximum Serum Concentration at steady-state (Cmax,ss)
Time Frame: Serum concentrations of YH35324 will be observed for 141 days after administration
|
To evaluate the PK profile of YH35324
|
Serum concentrations of YH35324 will be observed for 141 days after administration
|
Time to Maximum Serum Concentration at steady-state (Tmax,ss)
Time Frame: Serum concentrations of YH35324 will be observed for 141 days after administration
|
To evaluate the PK profile of YH35324
|
Serum concentrations of YH35324 will be observed for 141 days after administration
|
Accumulation ratio (Rac)
Time Frame: Serum concentrations of YH35324 will be observed for 141 days after administration
|
To evaluate the PK profile of YH35324
|
Serum concentrations of YH35324 will be observed for 141 days after administration
|
Change in serum free IgE level
Time Frame: Change in serum Free IgE will be observed for 141 days after administration
|
To evaluate the PD profile on serum IgE following multiple administrations of YH35324
|
Change in serum Free IgE will be observed for 141 days after administration
|
Change in serum total IgE level
Time Frame: Change in serum Total IgE will be observed for 141 days after administration
|
To evaluate the PD profile on serum IgE following multiple administrations of YH35324
|
Change in serum Total IgE will be observed for 141 days after administration
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in FcεRI expression on basophil surface
Time Frame: Changes in FcεRI expression will be observed for 141days after administration
|
To explore the PD profile on serum basophil following multiple administrations of YH35324
|
Changes in FcεRI expression will be observed for 141days after administration
|
Changes in allergen-induced skin prick wheal response
Time Frame: Changes in allergen-induced skin prick wheal response will be observed for 113 days.
|
To explore inhibition on allergens (allergy antigens) following multiple administrations of YH35324
|
Changes in allergen-induced skin prick wheal response will be observed for 113 days.
|
Changes in serum allergen specific IgE level
Time Frame: Changes in allergen-induced serum allergen specific IgE level will be observed for 141 days after administration
|
To explore inhibition on allergens (allergy antigens) following multiple administrations of YH35324
|
Changes in allergen-induced serum allergen specific IgE level will be observed for 141 days after administration
|
Incidence of serum anti-YH35324 antibodies
Time Frame: Incidence of serum Anti-YH35324 antibodies will be observed for 141 Days after administration
|
To explore the immunogenicity following multiple administrations of YH35324
|
Incidence of serum Anti-YH35324 antibodies will be observed for 141 Days after administration
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Hae-Sim Park, Ajou University School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- YH35324-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
De-identified individual participant data (including data dictionaries) that underline the results reported in study-related publications will be made available during the period beginning 1 year and ending 5 years after all trial primary and secondary endpoints were assessed. Only requests from researchers who provide a methodologically sound proposal will be reviewed and approved by the sponsor. The analysis type should be in accordance with aims in the proposal approved by the sponsor. Proposals should be directed to yhcho@yuhan.co.kr.
A summary of the study results will be posted in the publicly accessible database (i.e. clinicaltrials.gov) no later than 1 year after the study's primary completion date.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Healthy Subjects
-
Yuhan CorporationCompletedAtopic Healthy Subjects | Adult Subjects With Mild Allergic DiseasesKorea, Republic of
-
Bristol-Myers SquibbCompletedHealthy Subjects and Atopic Dermatitis SubjectsUnited Kingdom
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
NeuShen TherapeuticsNot yet recruiting
-
GEN İlaç ve Sağlık Ürünleri A.Ş.Sulfateq B.V.Recruiting
Clinical Trials on YH35324
-
Yuhan CorporationCompletedAtopic Healthy Subjects | Adult Subjects With Mild Allergic DiseasesKorea, Republic of
-
Yuhan CorporationRecruitingAllergic Disease | Chronic Spontaneous Urticaria | Cold Urticaria | Chronic Inducible UrticariaKorea, Republic of